<DOC>
	<DOCNO>NCT01895439</DOCNO>
	<brief_summary>1 . Expanding prim Bone Marrow ( BM ) - Mesenchymal Stem Cells ( MSCs ) clinical scale accord Good Laboratory Practice use xenogenic free medium instead previously use FCS . 2 . Assessing safety inject autologous BM-MSCs Multiple Sclerosis ( MS ) patient fail respond conventional treatment . 3 . Assessing therapeutic benefit participant trial per establish method .</brief_summary>
	<brief_title>Safety Efficacy Study Autologus Bone Marrow Mesenchymal Stem Cells Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>A clinical diagnosis definite MS accord revise McDonald Criteria . Expanded Disability Status Scale ( EDSS ) â‰¤ 6 Failure standard medical therapy Disease duration least three year prior enrollment . Pregnant lactate woman Previous treatment immunosuppressive agent last 12 month prior enrollment Recent MS relapse month prior enrollment Treatment oral parenteral steroid cause month prior enrollment Significant systemic medical disorder include cardiac , renal , hepatic , hematologic , immunologic endocrine disorder Previous treatment interferon glatiramer acetate 3 month prior enrollment Any contraindication magnetic resonance imaging ( MRI ) gadolinium contrast . Positive serology HIV , Hepatitis B Hepatitis C Any history malignancy exposure radiation time prior enrollment Any contraindication lumbar puncture Severe cognitive impairment would interfere patient 's ability understand sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bone marrow derive Mesenchymal Stem Cells</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Oligodendrocytes</keyword>
	<keyword>Neuroimmunology</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>